Many of the larger pharmaceutical companies are either experiencing sagging sales from the onset of generic competition or are facing a bleak future with no compounds in their pipelines to account for upcoming patent expirations on their top drugs. Schering-Plough (NYSE:SGP) is not one of them. After reporting its financial results yesterday, the drugmaker showed that in 2006 it has finally righted itself after a turnaround plan that took several years.
For the year, Schering's sales, adjusted to account for half of the revenue from the Merck (NYSE:MRK) cholesterol-drug collaboration, gained a solid 17% to $12.5 billion, and earnings came in at $1.1 billion, or $0.71 a share. Operating margins jumped 9 percentage points to 14% for 2006, even with a 17% increase in research-and-development spending. Since Schering is still in the fairly early stages of a multiyear turnaround, I would expect operating margins to continue climbing, as its sales ramp up more quickly than operating expenses.
Speaking of R&D, although Schering doesn't have the largest pipeline in the world, it can claim a few notable compounds, including its phase 2 protease inhibitor for hepatitis C, and there's also the possibility for label-expanding indications on Remicade and the Zetia/Vytorin franchise, which together represented nearly a fourth ($3.2 billion) of Schering's total revenue and experienced sales growth of almost 50% last year.
Without solid financials, any pharmaceutical firm's R&D is going to suffer, and without a strong pipeline, its financials are bound to hit a wall at some point. Considering that Schering-Plough is strong in both areas and is trading at 23 times analyst estimates of $1.07 for next year's earnings, investors would be smart to take a look at this pharmaceutical turnaround stock before it starts to get noticed again.
Merck is a former recommendation of the Motley Fool Income Investor newsletter service. To see what dividend-paying stocks are still making the cut, check out Income Investor free for 30 days.
Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has a disclosure policy.
